We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antibody Prevents Death of Neurons after Injury

By HospiMedica staff writers
Posted on 01 Apr 2004
A study has shown that the infusion of an antibody to the proNGF protein in an animal model can save injured neurons from death, suggesting a therapy for brain and spinal cord damage. More...
The study was published in the March 19, 2004, online Proceedings of the [U.S.] National Academy of Sciences.

Dead or dying nerve cells caused by stroke or neurodegenerative diseases such as Alzheimer's are known to trigger cell death in their healthy neighbors. The resulting cascade of cell deaths is often more devastating to the brain and spinal cord than the original injury, according to the researchers. They used an antibody to the proNGF protein, secreted by cells in an injured brain, to prevent its interaction with another protein, p75, found on the surface of injured neurons. By doing so, they were able to prevent the death of cortical neurons in mice and rats. The treatment increased nerve cell survival by more than 90%, compared to 61-66% in untreated animals.

Although the antibody used in the study is not appropriate for the treatment of humans, the study shows that proNGF is a viable target for discovering molecules that can be used to block the protein in patients. ProNGF is an unprocessed form of NGF, nerve growth factor.

"If you could identify a compound that could pass the blood-brain barrier and impair the binding of proneurotrophin to cell receptors, then it could be a potential drug that could be tested in animals and eventually patients,” noted Dr. Barbara Hempstead, professor of cardiovascular medicine at Weill Cornell Medical College (New York, NY, USA; www.med.cornell.edu) and a co-author of the study. Researchers at the University of Texas Southwestern Medical Center (USA), Ohio State University (USA), and the University of Saarland (Germany) also contributed to the study.




Related Links:
Weill Cornell Medical College

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.